Annovis Bio Inc. Company Profile
NYSE: ANVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Annovis Bio at a glance
Annovis Bio Inc. (NYSE: ANVS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Malvern, PA. Annovis Bio is led by Dr. Maria L. Maccecchini Ph.D. and employs about 7 people. The company's shares have traded publicly since 2020.
At a market capitalization of $44.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001477845, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Annovis Bio do?
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Annovis Bio Inc.
- Ticker
- NYSE: ANVS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Maria L. Maccecchini Ph.D.
- Employees
- 7
- Headquarters
- 101 Lindenwood Drive, Malvern, PA, United States
- Phone
- 484 875 3192
- Website
- annovisbio.com
- IPO year
- 2020
- Market cap
- $44.12M
- SEC CIK
- 0001477845
- Latest annual report
- 10-K · Mar 13, 2026
Companies similar to Annovis Bio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GANXGain Therapeutics Inc. | 0.9994 | -4.82% | $44.50M | vs ANVS |
| QUCYQuantum Cyber N.V. | 0.512 | -7.25% | $44.67M | vs ANVS |
| RLYBRallybio Corporation | 15.47 | -0.32% | $43.32M | vs ANVS |
| SPROSpero Therapeutics Inc. | 0.742 | -10.20% | $43.23M | vs ANVS |
| APLMApollomics Inc. Class A | 15.54 | -6.92% | $45.28M | vs ANVS |
| RNXTRenovoRx Inc. | 0.942 | -10.29% | $45.45M | vs ANVS |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 2.06 | -15.40% | $42.45M | vs ANVS |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs ANVS |